Comparative Pharmacology
Head-to-head clinical analysis: OGEN versus SAFYRAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OGEN versus SAFYRAL.
OGEN vs SAFYRAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estrogen replacement therapy; binds to estrogen receptors, activating gene transcription leading to cell proliferation and differentiation in target tissues.
Safyral is a combination of ethinyl estradiol and drospirenone. Ethinyl estradiol is an estrogen that suppresses gonadotropin release, preventing ovulation. Drospirenone is a progestin with anti-mineralocorticoid activity, which may reduce fluid retention, and anti-androgenic activity, which may improve acne. It also increases cervical mucus viscosity, impeding sperm penetration.
0.75 mg orally once daily, cyclically (3 weeks on, 1 week off) for moderate to severe vasomotor symptoms associated with menopause.
One tablet (drospirenone 3 mg/ethinyl estradiol 0.03 mg) orally once daily for 24 days, followed by 4 days of placebo.
None Documented
None Documented
Terminal elimination half-life of estrone is approximately 10-24 hours (mean ~14 hours); clinical context: permits once-daily dosing.
16.3 hours (range 12-21 hours) for drospirenone; 32.5 hours (range 24-42 hours) for ethinyl estradiol (EE); clinical context: steady-state achieved after 10 days for drospirenone, 7 days for EE
Renal elimination of conjugated metabolites (estrone sulfate, estradiol glucuronide) accounts for >95% of excretion; fecal elimination is <5%.
Urine (40% as metabolites, 20% unchanged; fecal 30% as metabolites; biliary excretion contributes to enterohepatic circulation, prolonging elimination)
Category C
Category C
Estrogen
Oral Contraceptive Progestin/Estrogen